Postponement of Special Meeting of Stockholders
BOSTON and SYDNEY — 5 June 2020 — GI Dynamics® Inc. (ASX:GID) (“GID” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, announces the postponement of the Special Meeting of Stockholders that was...Update: Proposed Delisting from the Official List of ASX – Formal Consent of ASX to Delist – Filing of Final Definitive Proxy Statement and Notice of Special Meeting
BOSTON and SYDNEY — 27 May 2020 — GI Dynamics® Inc. (ASX:GID) (“GID” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, confirms that further to its announcement of 11 May 2020, the Company has...Extension of Maturity Date of 2017 Note and Operational Update
BOSTON and SYDNEY — 4 May 2020 — GI Dynamics® Inc. (ASX:GID) (“GID” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, provides the following update regarding its operations and financing....GI Dynamics Announces Change to Board of Directors
BOSTON and SYDNEY — 30 March 2020 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, announces today that Timothy Barberich resigned as a non-executive director of its Board of...Videos
How EndoBarrier Works
EndoBarrier: Non-surgical Treatment for Patients with Type 2 Diabetes and …
Maintenance of Efficacy after EndoBarrier
UK First NHS EndoBarrier Service – Dr. Bob Ryder June …
BBC News Item
EndoBarrier treatment for diabetes & obesity following 1 year results …
